Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Patent
1975-07-18
1977-08-16
Friedman, Stanley J.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
A61K 31475
Patent
active
040426980
ABSTRACT:
A human being having the medical condition known as myasthenia gravis is treated by administering at least an effective amount of strychnine to ameliorate the symptoms of the condition but less than an amount which causes persistent fasciculation of the facial muscles of the human being. The amount of medication given is balanced against the body condition safely and easily by the skilled physician. Daily dosage rates, typically, range from about 1/6000 grain of strychnine, usually as the sulfate, per kilogram of body weight to as high as about 1/300 grain or more for the more severely afflicted, i.e., into the normally fatally toxic range, usually in the form of a 1/60 grain tablet administered at the rate of 1 to 3 tablets every 2 to about 16 waking hours as needed according to the severity of the condition. Mild cases are treated intermittently while severe cases require substantially daily treatment. Vitamin B complex co-administration maximizes the effectiveness of the strychnine and tends to diminish strychnine requirements, although no side reactions of strychnine have been observed. Strychnine requirements may also be reduced by co-administering deanol or neostigmine bromide or the dimethylcarbamate of 3-hydroxy-1-methylpyridinium.
REFERENCES:
chem. Abst. I-31 -- p. 8685.sup.4 (1937).
Chem. Abst. II-36 -- p. 7135.sup.2 (1942).
Current Therapy, (1963), p. 519, W. B. Saunders Corp., Phila. and London.
Perlstein et al., American Journal of Diseases of Children, 85-(1953),pp. 56-57.
LandOfFree
Treatment of myasthenia gravis and oral medication therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of myasthenia gravis and oral medication therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of myasthenia gravis and oral medication therefor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-361713